RE: RE: NONMEM 7 Update
Dear NONMEM users,
two years ago when we started (at Merck Serono) to discuss the necessary QA
documents for a "validated" NONMEM system the fact that NONMEM was open-source
played a major role in our risk analysis. In fact we conciously decided in
favor of open-source software also with regards of other tools (R, PsN, XPOSE)
associated with NONMEM.
I do not know to which degree system validation according to GxP standards is
affected in other commercial enterprices by the fact that NONMEM7 will no
longer be open-source. Specifically, I shall address that question here at my
new employer (AstraZeneca). I have also proposed to discuss the question of
NONMEM system validation at the upcoming PKUK meeting in Birmingham.
Please, do not apply the classification 'positive/negative reaction to new
encrypted NONMEM code' to my contribution. My work will not be negatively
affected by encryption, and I welcome the new estimation methods of NONMEM7.
Cheers,
Joachim Grevel
___________________________________________________
AstraZeneca R&D Charnwood
Clinical Pharmacology & DMPK
Bakewell Road, Loughborough, Leics LE11 5RH, England
Tel: +44 (0) 1509 645177
[email protected]
--------------------------------------------------------------------------
AstraZeneca UK Limited is a company incorporated in England and Wales with
registered number: 03674842 and a registered office at 15 Stanhope Gate, London
W1K 1LN.
Confidentiality Notice: This message is private and may contain confidential,
proprietary and legally privileged information. If you have received this
message in error, please notify us and remove it from your system and note that
you must not copy, distribute or take any action in reliance on it. Any
unauthorised use or disclosure of the contents of this message is not permitted
and may be unlawful.
Disclaimer: Email messages may be subject to delays, interception, non-delivery
and unauthorised alterations. Therefore, information expressed in this message
is not given or endorsed by AstraZeneca UK Limited unless otherwise notified by
an authorised representative independent of this message. No contractual
relationship is created by this message by any person unless specifically
indicated by agreement in writing other than email.
Monitoring: AstraZeneca UK Limited may monitor email traffic data and content
for the purposes of the prevention and detection of crime, ensuring the
security of our computer systems and checking Compliance with our Code of
Conduct and Policies.
Quoted reply history
-----Original Message-----
From: [email protected] [mailto:[email protected]]on
Behalf Of Serge Guzy
Sent: 03 July 2009 08:56
To: [email protected]; [email protected]; [email protected]
Subject: Re: [NMusers] RE: NONMEM 7 Update
I do have only one simple question. How many people took advantage from the
fact Nonmem was distributed as open source? If we are talking about a very
small percentage, is this discussion worthwhile? How many people except bob
bauer and may be somebody else I am not aware of are able to follow and
understand the cuirrent nonmem code?
Serge
_____
From: [email protected]
To: Ludden, Thomas ; [email protected]
Sent: Thu Jul 02 23:46:09 2009
Subject: [NMusers] RE: NONMEM 7 Update
Thomas
Didn't ICON consider that indeed, this decision might stimulate the divergence
of an open-source clade of NONMEM, somewhat like R stemmed out of S-plus? If a
small academic group starts to work in that direction, it would certainly be
quickly joined by many…
Thierry Buclin
Univ. Hospital, Lausanne
De : [email protected] [mailto:[email protected]] De la
part de Ludden, Thomas
Envoyé : jeudi, 2. juillet 2009 15:15
À : Eleveld, DJ; [email protected]
Cc : Krohn, Anthony
Objet : RE: [NMusers] NONMEM 7 Update
Dear All:
Icon Development Solutions has invested in the further development of NONMEM.
By mutual agreement with the University of California at San Francisco, NONMEM
7 is intellectual property belonging to IDS. However, IDS will continue to pay
royalties to UCSF.
The business plan under which NONMEM 7 was developed calls for the protection
of the I.P. involved. In addition, NONMEM 7 contains several updated routines
developed and owned by IMSL (Visual Numerics Inc.). Our agreement with IMSL
stipulates that we will not distribute their source code. The installer will
compile the software but will not allow the unencrypted source code to remain
on the users computer. The licensing agreement will also stipulate that any
attempt to access the source code will be a violation of the agreement.
Some source code will be left unencrypted for various reasons, one being the
need for users to change certain values in SIZES and perhaps other resource
routines.
Tom
Thomas M. Ludden Ph.D.
Vice-President, Pharmacometrics R&D
ICON Development Solutions
Tel: + 1 410 696 3040
Mob: + 1 410 258 2411
Fax: + 1 410 480 0776
Email: [email protected]
Web: www.icondevsolutions.com
_____
The information contained in this email message may contain confidential or
legally privileged information and is intended solely for the use of the named
recipient(s). No confidentiality or privilege is waived or lost by any
transmission error. If the reader of this message is not the intended
recipient, please immediately delete the e-mail and all copies of it from your
system, destroy any hard copies of it and notify the sender either by telephone
or return e-mail. Any direct or indirect use, disclosure, distribution,
printing, or copying of any part of this message is prohibited. Any views
expressed in this message are those of the individual sender, except where the
message states otherwise and the sender is authorized to state them to be the
views of XOMA.